Physician profile
Jamie P Sklar
NPI 1609239367
$1,644.43
in general payments reported to CMS, 2019-2025
21 companies · $585 in 2025
The $585 reported for 2025 was more than what 86% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $450 · 2024: $610 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $311.35 | 2023-2025 | Azstarys |
| Tris Pharma INC | $167.05 | 2023-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Collegium Pharmaceutical, INC. | $136.88 | 2025 | Jornay Pm |
| Neurelis, INC. | $132.79 | 2023-2025 | Valtoco |
| Biomarin Pharmaceutical INC. | $126.83 | 2023-2025 | Voxzogo 1.2mg |
| Ucb, INC. | $111.55 | 2023-2025 | Briviact |
| Ironshore Pharmaceuticals INC. | $106.34 | 2023-2024 | Jornay Pm |
| Acadia Pharmaceuticals INC | $85.60 | 2024-2025 | Daybue |
| Grifols USA, LLC | $59.57 | 2025 | Xembify |
| Medtronic, INC. | $59.26 | 2024 | Minimed 780g |
| Neos Therapeutics, Lp | $57.35 | 2023-2024 | Adzenys Xr-Odt |
| Tolmar, INC. | $56.66 | 2023-2025 | Fensolvi |
| Ascendis Pharma Endocrinology INC | $50.82 | 2025 | Skytrofa |
| Alexion Pharmaceuticals, INC. | $41.73 | 2023-2024 | Strensiq, Ultomiris |
| Mirum Pharmaceuticals, INC. | $23.34 | 2023 | Livmarli |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $23.25 | 2024 | Kristalose |
| Catalyst Pharmaceuticals, INC. | $22.44 | 2024 | |
| Azurity Pharmaceuticals, INC. | $20.38 | 2025 | Triptodur |
| Supernus Pharmaceuticals, INC. | $18.93 | 2025 | Qelbree |
| Novo Nordisk INC | $16.18 | 2024 | Rivfloza |
| Janssen Biotech, INC. | $16.13 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Sklar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.